A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer
Latest Information Update: 25 May 2026
At a glance
- Drugs Tarlatamab (Primary) ; Zocilurtatug pelitecan (Primary) ; Durvalumab
- Indications Small cell lung cancer
- Focus Adverse reactions
- Acronyms DeLLphi-313
- Sponsors Amgen
Most Recent Events
- 07 May 2026 Status changed from not yet recruiting to recruiting.
- 21 Apr 2026 New trial record